ArticleScientific reports2026
Glucosamine/chitosan blend surface-engineered rutin-loaded polymer/lipid hybrid nanoparticles for neuroprotection in induced schizophrenia model.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this investigation is to enhance the bioavailability and therapeutic activity of a hydrophobic flavonoid rutin, with reported neuroprotective potential, by developing an innovative drug delivery system. Rutin-loaded polymer/lipid hybrid nanoparticles comprising polycaprolactone and Geleol™ or Captex® were developed. They were assessed for entrapment efficiency, size, and zeta potential. The selected formula (F4) comprised equal ratios of polycaprolactone and Geleol™, revealed nanoparticle size (226.9 ± 38 nm) and a high entrapment efficiency value (78.84 ± 6.1%). A glucosamine/chitosan hydrochloride blend was used as a functional coating of F4. The studied formulations improved the release profiles of rutin, which were 33.60 ± 3.1%, 64.76 ± 5.8%, and 59.12 ± 4.3% for rutin, F4, and CF4, respectively. The efficacy of free rutin and the selected formulations was assessed using cuprizone-induced schizophrenia in mice. Behavioral, biochemical, and histopathological investigations demonstrated the therapeutic potential of rutin, which enhanced brain myelin basic protein (MBP) and neuregulin 1 (NRG1) levels, thereby restoring myelination. Rutin also stabilized dopamine and glutamate pathways, alleviating cognitive and neurochemical imbalances characteristic of schizophrenia. The designed rutin-loaded formulation proved more effective than the free rutin, and the functionalized formulation outperformed the uncoated formula. Collectively, these results underscore the promise of this delivery system, while further assessments for pharmacokinetics, brain uptake, and clinical investigations remain essential to verify its translational potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.